LIME1 (Lck interacting transmembrane adaptor 1) is a transmembrane adaptor protein that couples activation of B-cell antigen receptor (BCR) and T-cell antigen receptor (TCR) signaling with intracellular events including calcium mobilization and MAPK activation through recruitment of signaling molecules such as PLCG2, GRB2, and GRAP2 [UniProt annotation]. In the absence of TCR signaling, LIME1 may mediate CD4-dependent inhibition of T-cell activation [UniProt annotation]. Beyond its canonical immune functions, LIME1 has emerged as a disease-associated gene across multiple contexts. A GWAS integrative analysis identified LIME1 as a candidate gene associated with glioblastoma (GBM), though it was not among the highest-confidence therapeutic targets 1. LIME1 was identified as one of eight overexpressed, mutated tumor antigens with poor prognostic value in prostate adenocarcinoma and proposed as a potential mRNA vaccine candidate 2. In multiple sclerosis (MS), the MS-associated variant rs2256814 in LIME1 alters the balance of alternate transcripts in CD4+ and CD8+ T cells rather than changing overall gene expression levels 3. LIME1 expression was also included in a prognostic model for colorectal cancer risk assessment integrated with Candida albicans metabolic profiles 4. Additionally, LIME1 interacted with genetic ancestry to contribute to cancer survival disparities across multiple cancer types 5. In lung function studies, DNA methylation at the LIME1 locus (cg21201401) demonstrated a possible causal effect on forced expiratory volume 6.